Weak Demand For Covid Antivirals Dampens Roaring Sales

Pfizer could be left with up to 70 million surplus courses of Paxlovid by the end of 2022, data firm Airfinity warned, but the drug is still on track to be one of the year’s biggest.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive